open access

Vol 3, No 4 (1998)
Original papers
Published online: 1998-01-01
Submitted: 1999-03-11
Get Citation

Poorly differentiated loco-regionally advanced naso – and oropharyngeal carcinoma: results of neoadjuvant chemotherapy followed by radiotherapy

A. Radkowski, M. Reinfuss, J. Skołyszewski
DOI: 10.1016/S1507-1367(98)70170-1
·
Rep Pract Oncol Radiother 1998;3(4):67-73.

open access

Vol 3, No 4 (1998)
Original papers
Published online: 1998-01-01
Submitted: 1999-03-11

Abstract

Over the years 1986–1997, at the Centre of Oncology in Kraków, 82 patients (28 women, 54 men; mean age: 50.8 years) with poorly differentiatied naso- and oropharyngeal carcinoma with metastases to regional nodes (stage III and IV) received neoadjuvant chemotherapy followed by teleradiotherapy. The primary tumour was located in the nasopharynx in 57 patients (69.5%), in the tonsil – in 24 (29.3%), and in the base of the tongue (one patient). Chemotherapy cycles consisted of cisplatin in a dose of 100 mg/m2 administered intravenously on the first day, and 5-f1uorouracil in a dose of 1000 mg/m2 over days 1 to 5. Forty-seven (57.3%) patients received 3 cycles, 25 (30.5%) patients – 2 cycles, 8 (9.8%) patients – 1 cycle. After chemotherapy, patients received conventionally fractionated (200 cGy 5x a week) radiotherapy to the primary tumour (50–65 Gy) and regional nodes (50–70 Gy). The therapy was generally well tolerated, however two patients developed fatal late complications. Improvement in therapy results was observed when comparised with a historical group. Five-year overall survival was 52%. The degree of regression (PR + CR), following neoadjuvant chemotherapy, which appeared to depend on the number of chemotherapy cycles, is the main prognostic factor for this group of patients.

Abstract

Over the years 1986–1997, at the Centre of Oncology in Kraków, 82 patients (28 women, 54 men; mean age: 50.8 years) with poorly differentiatied naso- and oropharyngeal carcinoma with metastases to regional nodes (stage III and IV) received neoadjuvant chemotherapy followed by teleradiotherapy. The primary tumour was located in the nasopharynx in 57 patients (69.5%), in the tonsil – in 24 (29.3%), and in the base of the tongue (one patient). Chemotherapy cycles consisted of cisplatin in a dose of 100 mg/m2 administered intravenously on the first day, and 5-f1uorouracil in a dose of 1000 mg/m2 over days 1 to 5. Forty-seven (57.3%) patients received 3 cycles, 25 (30.5%) patients – 2 cycles, 8 (9.8%) patients – 1 cycle. After chemotherapy, patients received conventionally fractionated (200 cGy 5x a week) radiotherapy to the primary tumour (50–65 Gy) and regional nodes (50–70 Gy). The therapy was generally well tolerated, however two patients developed fatal late complications. Improvement in therapy results was observed when comparised with a historical group. Five-year overall survival was 52%. The degree of regression (PR + CR), following neoadjuvant chemotherapy, which appeared to depend on the number of chemotherapy cycles, is the main prognostic factor for this group of patients.

Get Citation

Keywords

neoadjuvant chemotherapy; radiotherapy; naso - and oropharyngeal cancer

About this article
Title

Poorly differentiated loco-regionally advanced naso – and oropharyngeal carcinoma: results of neoadjuvant chemotherapy followed by radiotherapy

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 3, No 4 (1998)

Pages

67-73

Published online

1998-01-01

DOI

10.1016/S1507-1367(98)70170-1

Bibliographic record

Rep Pract Oncol Radiother 1998;3(4):67-73.

Keywords

neoadjuvant chemotherapy
radiotherapy
naso - and oropharyngeal cancer

Authors

A. Radkowski
M. Reinfuss
J. Skołyszewski

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl